Samsung Biologics is a full-service provider offering development and cGMP manufacturing services. We deliver a broad range of services from development and manufacturing to fill and finish, covering both clinical molecules and commercial products. Established in April 2011, Samsung Biologics will transform the global healthcare industry over the next decade through our quality, technology and innovation. Our facilities are custom designed for monoclonal & recombinant production with maximum flexibility. Our one-stop services include cell line generation, process and analytical method development, analytical services (characterization, comparability, IPC, lot release & stability), and clinical and commercial bulk cGMP manufacturing of drug substance and drug product. We also provide quality assurance and quality control services, as well as worldwide regulatory compliance standards & support for our customers. We are centrally located in the heart of Asia, within 20 minutes of Incheon International Airport.



Samsung Biologics is a reliable partner for seamless tech transfers, clinical & commercial manufacturing, aseptic fill/finish and analytical testing. From the beginning of our partnership, you will have a dedicated project management team to walk you through the entire journey of the product development & manufacturing of your product. We are committed to operational excellence in cGMP manufacturing and quality assurance to deliver value to our clients.

As your most qualified world’s leading CDMO partner, Samsung Biologics delivers your success to IND & BLA Faster & Better with maximum flexibility. We promise the Best.

Samsung Biologics provides an ‘End-to-End’ biosafety testing service for CMO / CDO clients. CRO services cover development stage to DS products for lot release tests of Mycoplasma & Virus detection. Our service is expanding to Cell bank manufacturing, Cell line characterization and Viral clearance study.


Samsung Biologics

300 Songdo Bio Way, Yeonsu-gu

Incheon, 21987


Phone: +82 32 455 3114

Contact: Jinyong Kim


  • Key Considerations When Outsourcing An Aseptic Fill/ Finish Project To A CMO Partner

    In this presentation, we discuss key elements to consider when choosing to outsource drug production. We will cover the importance of seeking the right partnerships to help overcome complex challenges and Samsung Biologics’ responsibility to leverage capabilities, optimize process efficiency, assure successful delivery, and provide the assurance of secure commercial product supply.

  • Get To IND Faster

    Expediting development timeline is directly related to obtaining IND clearance and starting phase 1 study faster. This webinar describes how you can get to IND faster through our accelerated & high performance proprietary cell line. We will present our 3 month cell line development timeline and high quality cell line with outstanding productivity. We hope to share how our Faster & Better approach, which can be applicable to your molecule's successful development path to IND.

  • Biopharmaceutical Process Characterization

    Here we present process development and characterization strategies required to support commercial scale manufacture of antibody therapeutics. 


  • S-CHOice Cell Line Expression Technology

    Samsung Biologics proudly presents the official launch of their proprietary cell line, S-CHOice, a high-performing technology to start your successful therapeutics development journey. We can now offer our clients even more promising options in bringing their molecule faster and better to the market with world-class client satisfaction.

  • Building A Better Future

    Samsung Biologics’ vision is to enrich human life with technology and innovation. By continuously innovating our people, process, and portfolio, we will fulfill our mission to become the most trusted partner to our clients working together to achieve "Better Life" for humanity through biomedicines.